Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nueva diana terapéutica para restaurar la función leucocitaria en pacientes con insuficiencia renal crónica

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20160303002
Publicado:
03/05/2016
Caducidad:
03/05/2017
Resumen:
Científicos del departamento de Anestesiología de una universidad alemana han sido capaces de restaurar la defensa del huésped y control de patógenos en ratones con insuficiencia renal crónica (modelo para pacientes con insuficiencia renal crónica), mejorando la supervivencia gracias a la aplicación de un anticuerpo neutralizante del FGF23 (factor de crecimiento de fibroblastos 23). Los inhibidores del FGF23 ejercen efectos beneficiosos restaurando las funciones leucocitarias que son críticas en la defensa del huésped durante la infección. La universidad busca licenciatarios o socios interesados en continuar con el desarrollo.

Details

Tittle:
Novel therapeutic target for restoring leukocyte function in Chronic Kidney Disease (CKD) patients
Summary:
A technology transfer office in Germany (Bavaria) represents a known German university. Scientists of its Department of Anaesthesiology were capable of restoring host defense and pathogen clearance in mice with chronic kidney failure ( model for Chronic Kidney Disease (CKD) patients) and thereby significantly improving their survival by applying a FGF23 (fibroblast growth factor 23) neutralizing antibody. They are looking for licensees or partners for further development.
Description:
A German university represented by a technology transfer office in Bavaria has been researching in chronic kidney diseases (CKD), which is a common condition in developed countries. Little information is available about the mechanism how Chronic Kidney Disease affects host defense. Despite the availability of conventional infection therapy (including antibiotics), infection-related hospitalizations contribute substantially to excess morbidity and mortality in CKD, and infection is the second leading cause of death in this population. There is thus an urgent need for novel means and methods in treating CKD, and in particular for treatment and prevention of infection in CKD. It is the object of the present invention to comply with this need.

It was shown in a mouse model that FGF23 (fibroblast growth factor 23) contributes considerably to the reduction of functional efficiency of the immune system commonly observed in chronic kidney disease patients. Specifically, FGF23 was found to inhibit leucocyte recruitment to sites of infection, leading to an impaired clearance of pathogens from the body and increased mortality. Surprisingly, it was found out that different FGF23 inhibitors were capable of restoring host defense and pathogen clearance, thereby significantly improving survival. Moreover, it could be shown that FGF23 affects different leucocyte functions, including recruitment to infected tissue, adhesion, ICAM-1 (Intercellular Adhesion Molecule 1) binding (and rolling velocity), superoxide production, as well as integrin-dependent phagocytosis and transendothelial migration.

It can therefore be envisioned that FGF23 inhibitors exert their beneficial effects by restoring these leucocyte functions that are critical to host defense during infection.

A partner is searched for further development of FGF23 inhibitors as therapeutics for enhancing immune defense in CKD patients.
Advantages and Innovations:
With this new knowledge it is possible to develop therapeutics for restoring leukocyte function in Chronic Kidney Disease patients and reduce infections in CKD patients.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
A first patent application has been filed for Luxemburg. Patent filing under PCT is planned.

Partner sought

Type and Role of Partner Sought:
Type of Partner sought:
The Partner should be working in the field of chronic kidney disease therapies or in the field of prevention of infection.

Specific area of activity of the Partner:
Development and production of products for treatment and prevention of infection in chronic kidney disease.

Task to be performed:
The partner should be able to develop a product for treatment and prevention of infection in chronic kidney disease out of the given information.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001016 Fisiología
06001012 Investigaciones médicas
06001015 Productos farmacéuticos / medicamentos